WHO ICTRP trial
rEaL-world pharmacokinetics of Immune Checkpoint InhibiTors (ELICIT)
NL-OMON51955 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON51955 |
|---|---|
| Public title | rEaL-world pharmacokinetics of Immune Checkpoint InhibiTors (ELICIT) |
| Scientific title | rEaL-world pharmacokinetics of Immune Checkpoint InhibiTors (ELICIT) - ELICIT |
| Primary sponsor | Radboud Universitair Medisch Centrum |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Observational invasive |
| Phase | 4 |
| Countries | The Netherlands |
| Conditions | lung cancer NSCLC;10038666;lung cancer;NSCLC |
| Interventions | ;immune-checkpoint inhibitor;pharmacokinetics |
| Registration date | Jun 9, 2022 |
| Target size | 100 |
| Secondary IDs | 2021-001509-66;NCT04833075;NL77286.091.21 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: